Search
Dordaviprone
go.drugbank.com/drugs/DB14844ApprovedInvestigationalDordaviprone is a first-in-class small molecule imipridone. On August 6, 2025, dordaviprone was granted accelerated approval by the FDA. … activation of mitochondrial caseinolytic protease P (ClpP), antagonism of the dopamine D2 receptor,[L53833] activation of Activating Transcription Factor 4 (ATF4), and induction of endoplasmic reticulum (ER
Synonyms: 7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo(1,2-A)pyrido(3,4-E)pyrimidin-5(4H)-one, 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimidin-5(1H)-oneSparsentan
go.drugbank.com/drugs/DB12548ApprovedInvestigationalaccelerated approval based on reduction of proteinuria. … [L45300] On April 24, 2024, sparsentan was granted conditional marketing authorization by the European Commission for the treatment of adults with primary IgAN.[L51559]
Categories: Agents Acting on the Renin-Angiotensin SystemPoliglusam
go.drugbank.com/drugs/DB11234ApprovedInvestigationalIt is also reported to have an effect on protein aggregation, emulsification capacity, film-forming ability, clarifying ability, and fatty acid absorption capability [L999]. … In comparison, commercial poliglusam is derived from deacetylation of chitin contained in the shells of various sea crustaceans such as shrimps [L999].
Mixtures: Ariella Nail Repair PenCategories: Compounds used in a research, industrial, or household settingSiponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigationalIt was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. … [L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
AVR118
go.drugbank.com/drugs/DB04979InvestigationalAVR118 is being studied for the promise shown in its ability to mitigate the toxic side effects of other drugs (including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment … for its ability to stimulate the immune system to attack tumor cells (especially those cancer cells that have been damaged by chemotherapeutic agents) and for its ability to treat cachexia (wasting) in
Cabozantinib
go.drugbank.com/drugs/DB08875ApprovedInvestigationalCabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. … [L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019
Promethazine
go.drugbank.com/drugs/DB01069ApprovedInvestigational[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] … Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946.
Synonyms: N,N,α-trimethyl-10H-phenothiazine-10-ethanamine, N,N,alpha-trimethyl-10H-phenothiazine-10-ethanamineMixtures: COPHADYL-E COUGH LINCTUSSiltuximab
go.drugbank.com/drugs/DB09036ApprovedInvestigationalSiltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology.
Alpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalAlpelisib is marketed under the trade name Piqray and is available as oral tablets. … Alpelisib was granted FDA approval on 24 May 2019.
Chlorambucil
go.drugbank.com/drugs/DB00291ApprovedInvestigationalAlthough it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Synonyms: N,N-di-2-chloroethyl-γ-p-aminophenylbutyric acid, N,N-di-2-chloroethyl-gamma-p-aminophenylbutyric acid